NCT06189209 - Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 4, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

March 31, 2026

Conditions

Triple Negative Breast Cancer (TNBC)

Interventions

DRUG

Tenalisib

Tenalisib will be administered 800mg/ 400mg BID, orally

Trial Locations (7)

RECRUITING

Tata Memorial Centre, Mumbai

RECRUITING

Mumbai Oncocare Centre, Mumbai

RECRUITING

Sahyadri Super Speciality Hospital, Pune

NOT_YET_RECRUITING

Nizams Institute of Medical Science, Hyderabad

RECRUITING

HCG City Cancer Center, Vijayawada

RECRUITING

Narayana Hrudayala Majumdar Shaw Hospital, Bangalore

NOT_YET_RECRUITING

Meenakshi Mission Hospital & Research Center, Madurai